Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Rajni Sethi, Nicholas SanfilippoDepartment of Radiation Oncology, New York University Langone Medical Center, New York, NY, USAAbstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some pa...
Guardado en:
Autores principales: | Rajni Sethi, Nicholas Sanfilippo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/72f39d373bb845b7bb19979e8e7aae54 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn UW, et al.
Publicado: (2013) -
Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders
por: Grzesiak K, et al.
Publicado: (2018) -
Degarelix and its therapeutic potential in the treatment of prostate cancer
por: Christian Doehn, et al.
Publicado: (2009) -
Is there an optimal management for localized prostate cancer?
por: Jaspreet Singh, et al.
Publicado: (2010) -
Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making
por: Nnabugwu II, et al.
Publicado: (2014)